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The advent of highly active antiretroviral therapy (HAART)
in 1996 revolutionized life expectancy and quality of life
of people infected by HIV in the developed Countries.
Nowadays, HIV-infected patients can positively think that
their life expectancy is comparable to that of people of the
same age and with the same pattern of risk factors Indeed,
there are clear demonstrations that mortality patterns in
most nonintravenous drug users HIV infected individuals
with high CD4+ T-cell counts restored by HAART are
similar to those in the general population [1]. Unfortunately,
however, not all HIV-infected patients on HAART are able
to restore their CD4+ T-cell count, and signs of immune
deficits or immune activation persist in most individuals
despite an apparent control of HIV viremia and a mere
increase of the CD4+ T-cell number. This persistent immune
deregulation has been correlated, and it is believed to be—at
least in part—in the causal pathway of end-organ diseases
(such as non-AIDS-defining neoplasias or cerebrovascular
events) that continue to aﬀect our patient population. So,
biological age of our patients has been estimated to be 10–15
higher than the current age for the risk of these complications
[2]. It is therefore important to better understand risk
factors and immune correlates of such persistent immune
de-regulation, how to measure and how to correct it. For this
reason, immunemodulator strategies are eagerly awaited as a
complement to HAART. In this special issue on immunity to
HIV, we provide high quality papers that address these issues.
The paper by S. C. Gaardbo et al. provides an in-depth
review on possible reasons andmechanisms of an incomplete
immune recovery. M. R. Pinzone et al. focuses on persistent
immune replication in cellular or anatomical sanctuaries,
how to measure such replication, and the need of new
therapeutic strategies to target the latent viral reservoirs. To
complete this scenario, Cotugno et al. contextualize these
issues to vertically HIV-infected children. In addition, they
describe immune responses to vaccinations as a means
to detect and explain suboptimal reconstitution in these
patients. Importantly, S. Duggal et al. underline the complex
interactions between HIV, immune function, and nutrition.
This paper merits consideration in light of the fact that
the most HIV-infected patients reside in resource limited
settings; malnutrition is a dangerous ally to HIV in these
areas of the word, so we need a political commitment to fight
this proudly.
C. Tincati et al. studied a facet of persistent immune
activation as a possible cause of suboptimal immune
response. The authors observed that in vitro stimulation by
lipopolysaccharide (LPS) produced a CD8+CD38+ upregu-
lation in patients with smaller CD4+ T-cell recovery after
HAART. This finding allowed the authors to speculate that
the mere induction of CD38 on CD4+ cells may not entirely
account for the immune activation induced by LPS in HIV-
infected patients. Therefore, further studies are needed to
better understand the regulation of T-cell activation. Rather
simplistic theories may not be true.
HIV-associated neurocognitive disorder is an emerging
complication in the era of HAART. It can be explained,
at least in part, by inadequate penetration of antiretroviral
drugs across the blood brain barrier, but also immune
activation or persistent viremia in the macrophage lineage
cells in the brain may have a role. The paper by Airoldi
et al. adds a piece to the puzzle of the relationship
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between immune activation parameters and HIV load in the
cerebrospinal fluid (CSF) of patients with HIV-associated
neurocognitive disorders (HANDs). The main finding is
that immune activation is hyperexpressed in patients with
HAND and less sensitive to HAART than the HIV load
in the CSF. It has to be seen whether immune activation
is a better means to monitor the eﬀect of HAART in
these patients than the mere quantification of HIV RNA.
So we probably need a multidimensional algorithm for
diagnosis and followup of HAND including virological
methods, immunological tests, neuroimaging techniques,
and neuropsychological tests. Moreover, it is interesting
to note that what happens in the peripheral blood does
not fully account for what it is happening in the central
nervous system as a sanctuary. This may be important and
relevant for diagnosing andmonitoring complications in this
compartment.
Further two papers deal with B-cell responses, a topic
that has been investigated not so in depth as T-cell responses.
The review by Poudrier et al. concludes that host capacity
to maintain dendritic cell homeostasis at mucosal sites, and
therefore an eﬀective B-cell response against HIV, have a key
role to better control the infection. In their original work,
M. Fogli at al. noted a dramatic expansion of exhausted
tissue-like memory B cells related to an increase of Torque
teno virus (TTV) which was assumed to reflect a functional
competency of the immune function. Interestingly, such a
defect was noted even in patients with a quite preserved
CD4+ T-cell count (>350/mm3), possibly reinforcing the
need of an earlier treatment.
Lastly, it is clear that HAART is not suﬃcient to entirely
restore the immune function damaged by HIV. So, vaccine
and immune-modulatory therapy should be experimented.
The paper by Li et al. used a DNA prime/fowlpox virus
boost regimen to immunize rhesus macaques. This study
showed that the vaccine was able to induce a strong immune
response and increase the CD4/CD8 ratio in the vaccinated
animals. Ries et al. provided an extensive review on blocking
type I interferon production as a means to reduce immune
deregulation. This concept should clearly be taken into
consideration as an opportunity for adjuvant immune-
modulatory therapies in HIV infection.
In conclusion, this special issue encompasses a broad
range of cutting-edge topics in HIV research. We feel
that they will enrich the current body of the literature
significantly.
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